What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Core Insights - Abbott Laboratories (ABT) is valued at a market cap of $217 billion and operates in the healthcare sector, focusing on medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals [1] Financial Performance - Analysts expect ABT to report a profit of $1.50 per share for fiscal Q4 2025, reflecting an 11.9% increase from $1.34 per share in the same quarter last year [2] - For the current fiscal year ending in December, ABT is projected to report a profit of $5.15 per share, up 10.3% from $4.67 per share in fiscal 2024, with an expected EPS growth of 9.9% year-over-year to $5.66 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, ABT shares have gained 8.8%, underperforming the S&P 500 Index's 14.8% return and the State Street Health Care Select Sector SPDR ETF's 11.8% increase [4] - On October 15, ABT shares fell by 2.9% following mixed Q3 earnings results, with net sales increasing 6.9% year-over-year to $11.4 billion but missing consensus estimates due to a decline in the diagnostic products segment [5] Analyst Ratings - Wall Street analysts maintain a "Strong Buy" rating for ABT, with 19 out of 27 analysts recommending "Strong Buy," two suggesting "Moderate Buy," and six indicating "Hold." The mean price target for ABT is $146.69, suggesting a 17.5% potential upside from current levels [6]